Stockwatch: when less ESA is more
This article was originally published in Scrip
Executive Summary
The FDA's recommendation on lower doses of erythropoiesis-stimulating agents (ESAs) to treat anaemia, announced on the afternoon of 24 June 2011, had investors scurrying for the exits wiping about $830m from Amgen's market capitalisation. In retrospect, this looks like a knee-jerk reaction to the latest in a long line of safety and commercial concerns for the ESA drug class. What may be lost in the admittedly short-term perspective that investors have taken is that regulatory actions and their reinforcement by the medical profession and reimbursement norms also serve to tighten Amgen's grip on the ESA franchise.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.